Journal article
Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer
Future oncology (London, England), Vol.11(18), pp.2563-2574
09/01/2015
DOI: 10.2217/fon.15.105
PMID: 26314701
Abstract
Aim: To evaluate the efficacy and safety of maintenance treatment with oral cyclophosphamide (Cy) and bevacizumab (Bev) in patients with recurrent ovarian cancer. Patients & methods: Induction treatment consisted of cisplatin, epirubicin, Cy and Bev every 3 weeks, for a maximum of six cycles. Maintenance treatment consisted of oral Cy 50 mg, days 1–14 and Bev 15 mg/kg, every 3 weeks until disease progression occurred. Results: In total, 39 patients were enrolled: after induction chemotherapy, the objective response was 74.3%. The median progression-free survival was 13.3 months, and the median overall survival was 33.2 months. Toxicity during maintenance treatment was mild. Conclusion: Maintenance with Cy and Bev may achieve encouraging results in terms of progression-free survival and overall survival in recurrent ovarian cancer patients.
Details
- Title: Subtitle
- Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer
- Creators
- Roberto Petrioli - University of SienaGiandomenico Roviello - University of SienaAnna Ida Fiaschi - University of SienaLetizia Laera - University of SienaSalvatora Tindara Miano - University of SienaDaniele Marrelli - University of SienaFranco Roviello - University of SienaVincenzo Bianco - Policlinico Umberto IEdoardo Francini - Policlinico Umberto I
- Resource Type
- Journal article
- Publication Details
- Future oncology (London, England), Vol.11(18), pp.2563-2574
- DOI
- 10.2217/fon.15.105
- PMID
- 26314701
- NLM abbreviation
- Future Oncol
- ISSN
- 1479-6694
- eISSN
- 1744-8301
- Number of pages
- 12
- Language
- English
- Date published
- 09/01/2015
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985221146502771
Metrics
2 Record Views